MAPK3 and neoplasm: Preclinical studies have demonstrated that ERα stimulation results in reduced ERK1/2 (Extracellular signal-Regulated Kinases 1 and 2) activity, thereby decreasing tumor cell proliferation and slowing tumor progression [65].